Skip to main content
SpringerLink
Log in

Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

To determine the receipt and impact of adjuvant therapy on overall survival (OS) for anaplastic astrocytoma (AA). Data were extracted from the National Cancer Data Base (NCDB). Chi square test, Kaplan–Meier method, and Cox regression models were employed in SPSS 22.0 (Armonk, NY: IBM Corp.) for data analyses. 4807 patients with AA diagnosed from 2004 to 2013 who underwent surgery were identified. 3243 (67.5 %) received adjuvant chemoRT, 525 (10.9 %) adjuvant radiotherapy (RT) alone, 176 (3.7 %) adjuvant chemotherapy alone and 863 (18.0 %) received no adjuvant therapy. Patients were more likely to receive adjuvant chemoRT if they were diagnosed in 2009-2013 (p = 0.022), were ≤ 50 years (p < 0.001), were male (p = 0.043), were Asian or White race (p < 0.001), had private insurance (p < 0.001), had income ≥$38,000 (p < 0.001), or underwent total resection (p < 0.003). Those who received adjuvant chemoRT had significantly better 5-year OS than the other adjuvant treatment types (41.8 % vs. 31.2 % vs. 29.8 % vs. 27.4 %, p < 0.001). This significant 5-year OS benefit was also observed regardless of age at diagnosis. Of those undergoing adjuvant chemoRT, those receiving ≥59.4 Gy had significantly better 5-year OS than those receiving <59.4 Gy (44.4 % vs. 25.9 %, p < 0.001). There was no significant difference in OS when comparing 59.4 Gy to higher RT doses. On multivariate analysis, receipt of adjuvant chemoRT, age at diagnosis, extent of disease, and insurance status were independent prognostic factors for OS. Adjuvant chemoRT is an independent prognostic factor for improved OS in AA and concomitant chemoRT should be considered for all clinically suitable patients who have undergone surgery for the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62

    Article  PubMed  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed  PubMed Central  Google Scholar 

  3. Killela PJ, Pirozzi CJ, Reitman ZJ et al (2014) The genetic landscape of anaplastic astrocytoma. Oncotarget 5:1452–1457

    Article  PubMed  Google Scholar 

  4. Rao SA, Srinivasan S, Patric IR et al (2014) A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One 9:e85200

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mayer A, Schneider F, Vaupel P et al (2012) Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. Int J Oncol 41:1260–1270

    PubMed  PubMed Central  Google Scholar 

  6. Dreyfuss JM, Johnson MD, Park PJ (2009) Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 8:71

    Article  PubMed  PubMed Central  Google Scholar 

  7. Stupp R, Reni M, Gatta G et al (2007) Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63:72–80

    Article  PubMed  Google Scholar 

  8. Brandes AA, Nicolardi L, Tosoni A et al (2006) Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 8:253–260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. See SJ, Gilbert MR (2004) Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol 31:618–634

    Article  PubMed  Google Scholar 

  10. Prados MD, Gutin PH, Phillips TL et al (1992) Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23:3–8

    Article  CAS  PubMed  Google Scholar 

  11. Barker CA, Chang M, Beal K et al (2014) Survival of patients treated with radiation therapy for anaplastic astrocytoma. Radiol Oncol 48:381–386

    Article  PubMed  PubMed Central  Google Scholar 

  12. Shonka NA, Theeler B, Cahill D et al (2013) Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol 113:305–311

    Article  CAS  PubMed  Google Scholar 

  13. Scoccianti S, Magrini SM, Ricardi U et al (2012) Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol 14:798–807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Strowd RE, Abuali I, Ye X et al (2016) The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. J Neurooncol 127:165–171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kizilbash SH, Giannini C, Voss JS et al (2014) The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol 120:85–93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Tanaka S, Meyer FB, Buckner JC et al (2012) Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. J Neurooncol 110:227–235

    Article  PubMed  Google Scholar 

  17. National Cancer Data Base (NCDB). American College of Surgeons. https://www.facs.org/quality-programs/cancer/ncdb

  18. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  CAS  PubMed  Google Scholar 

  19. Ron IG, Gal O, Vishne TH et al (2002) Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial. Am J Clin Oncol 25:296–302

    Article  PubMed  Google Scholar 

  20. Grimm SA, Pfiffner TJ (2013) Anaplastic astrocytoma. Curr Treat Options Neurol 15:302–315

    Article  PubMed  Google Scholar 

  21. Prados MD, Seiferheld W, Sandler HM et al (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147–1152

    Article  CAS  PubMed  Google Scholar 

  22. van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350

    Article  PubMed  Google Scholar 

  23. Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343

    Article  CAS  PubMed  Google Scholar 

  24. Minniti G, Scaringi C, Arcella A et al (2014) IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol 118:377–383

    Article  CAS  PubMed  Google Scholar 

  25. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  CAS  PubMed  Google Scholar 

  26. Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The medical research council brain tumour working party. Br J Cancer 64:769–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Nomiya T, Nemoto K, Kumabe T et al (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106:575–581

    Article  PubMed  Google Scholar 

  28. Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642

    Article  PubMed  Google Scholar 

  29. Fulton DS, Urtasun RC, Scott-Brown I et al (1992) Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I–II dose response study. J Neurooncol 14:63–72

    Article  CAS  PubMed  Google Scholar 

  30. Shi R, Diaz R, Shi Z et al (2016) The effect of payer status on survival of patients with stage I/II non-small cell lung cancer: NCDB 1998–2011. Anticancer Res 36:319–326

    CAS  PubMed  Google Scholar 

  31. Roetzheim RG, Pal N, Gonzalez EC et al (2000) Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 90:1746–1754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kwok J, Langevin SM, Argiris A et al (2010) The impact of health insurance status on the survival of patients with head and neck cancer. Cancer 116:476–485

    Article  PubMed  PubMed Central  Google Scholar 

  33. Byers TE, Wolf HJ, Bauer KR et al (2008) The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer 113:582–591

    Article  PubMed  Google Scholar 

  34. Phase III trial of anaplastic glioma without 1p/19q LOH (CATNON). European Organisation for Research and Treatment of Cancer 26053-22054 (NCT00626990). https://clinicaltrials.gov/ct2/show/NCT00626990?term=NCT00626990&rank=1

  35. Radiation therapy with concomitant and adjuvant temozolomide versus radiation therapy with adjuvant pcv chemotherapy in patients with anaplastic glioma or low grade glioma. Alliance for Clinical Trials in Oncology N0577 (NCT00887146). https://clinicaltrials.gov/ct2/show/NCT00887146?term=NCT00887146&rank=1

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Rush University Medical Center, 500 S. Paulina St., Chicago, IL, 60612, USA

    Jacob Y. Shin & Aidnag Z. Diaz

Authors
  1. Jacob Y. Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aidnag Z. Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob Y. Shin.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shin, J.Y., Diaz, A.Z. Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. J Neurooncol 129, 557–565 (2016). https://doi.org/10.1007/s11060-016-2210-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2210-1

Keywords

Search

Navigation